1558 — Yichang Hec Changjiang Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- HK$13.97bn
- HK$14.88bn
- CNY3.72bn
Brief: YiChang HEC ChangJiang Pharmaceutical Sees Net Profit Attributable Of RMB68 Million For Year
Brief: Yichang Hec Changjiang Pharmaceutical Sees Record Net Profit Attributable Of RMB68 Million For Year
Brief: Yichang Hec Changjiang Pharmaceutical Updates On Partial Repurchase Of H Share Convertible Bonds
Brief: Yichang Hec Changjiang Pharmaceutical Says Co And Shenzhen Hec Industrial Entered Framework Agreement
Brief: Yichang Hec Changjiang Pharmaceutical Says To Purchase Bonds In Aggregate Principal Amount $28.9 Mln
Brief: Yichang Hec Changjiang Pharmaceutical Announces Disposal Of Target Equity In Sunshine Lake Pharma
Brief: Yichang Hec Changjiang Pharmaceutical Says Insulin Aspart 30 Injection Obtained Approval For Launch From China NMPA
Brief: Yichang Hec Changjiang Pharmaceutical Says Insulin Aspart Injection Obtained Approval For Launch From NMPA
U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug (updated)
U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug
Novartis to take U.S. drug patent case to Supreme Court
Brief: Yichang Hec Changjiang Pharmaceutical Says Co Entered Bond Purchase Agreement With Holders
Brief: YiChang HEC Changjiang Pharmaceutical Posts HY Loss And Total Comprehensive Income Attributable Of RMB32.8 Million
Brief: Yichang Hec Changjiang Pharmaceutical Posts FY Revenue RMB913.79 Million, Down 61.08%
Brief: Yichang Hec Changjiang Pharmaceutical Posts Operating Income Of RMB578 Mln For Two Months
Brief: Yichang Hec Changjiang Pharmaceutical Sees A Net Loss Attributable Of About RMB546 Million To RMB630 Million For Year
Brief: Yichang Hec Changjiang Pharmaceutical Says Azithromycin Tablets Obtained Approval For Launch From China NMPA
Brief: Yichang Hec Changjiang Pharmaceutical Says Metoprolol Succinate Sustained-Release Tablets Obtained Approval For Launch From China NMPA
HK-listed YiChang HEC jumps most in 6 weeks on drugs' launch approval